BLOK Technologies Inc. (“BLOK Tech” or the “Company”) (CSE:BLK) (FRANKFURT:2AD) is pleased to announce that Justin Kausel has joined the Company as Director of Business Development for BLOK Tech’s 100% wholly-owned subsidiary Greenstream Networks Inc. (“Greenstream”). Justin will be responsible for the Company’s business development strategy and implementation of new business opportunities in the cannabis sector for Greenstream.

Mr. Kausel is an energetic and driven business professional who for more than a decade has been developing start-ups with lasting success. With a background in business development, marketing and operations management, Justin is currently Director of Business Development for Veritas Pharma and has held positions as VP Marketing, Vice-President and Managing Director. Justin has seen success as a strategic consultant for three technology companies in the dental, healthcare and blockchain fields. He has extensive strategic & tactical experience from the start-ups in both Canadian and international markets. Justin has forged enduring relationships with C-suite teams at some of the world’s largest B2B and B2C companies and include Cadillac Fairview, Ivanhoe Cambridge, Oxford, Morguard, Audi, Bell, L’Oreal, Lexus, and Mercedes.


Mr. Kausel also holds a Bachelor of Arts in International Relations from Concordia University.

“Justin brings to Greenstream great relationship and networking skills. We are tremendously excited to have him as part of the Greenstream team. His business insight and divergence of experience across many business disciplines will be a great asset to driving strategy and bringing shareholder value to the Company.” said Greenstream CTO Joel Yaffe. “As we look at the significant progress we are making with our current Greenstream blockchain development project, we look to augment this by working closely with Licenced Producers that will help position the Company for future growth.”

The Company also announces the issuance of 775,000 stock options at $0.185 to directors, management, and consultants of the Company for a term of twelve (12) months.

About BLOK Technologies Inc.
BLOK Technologies Inc. is a public company that invests in and develops emerging companies in the blockchain technology sector. The Company’s approach is to provide capital, technology and management expertise to the companies it develops. With core technology being developed for the leading cannabis supply chain integrity network, BLOK Tech continues to grow its business into adjacent industries and emerging technologies. The Company systematically identifies early-stage technologies with potential to disrupt and innovate within their industry and invests the necessary resources to ensure the success of their projects.

For additional information regarding BLOK Technologies and other corporate information, please visit the Company’s website at BLOKTECHINC.COM

For further information, please contact:

James Hyland, B.Comm.
Vice President Corporate Development, Director
(604) 442-2425
jamie@bloktechinc.com

ON BEHALF OF THE BOARD OF DIRECTORS

“Robert Dawson”
President & CEO

Statements in this news release may be viewed as forward-looking statements. Such statements involve risks and uncertainties that could cause actual results to differ materially from those projected. There are no assurances the company can fulfill such forward-looking statements and the company undertakes no obligation to update such statements. Such forward-looking statements are only predictions; actual events or results may differ materially as a result of risks facing the company, some of which are beyond the company’s control.

Click here to connect with BLOK Technologies Inc. (CSE:BLK) (FRANKFURT:2AD) for an Investor Presentation

Source: globenewswire.ca

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less